ES2612830T3 - Control electrónico de sistema de administración de fármacos - Google Patents
Control electrónico de sistema de administración de fármacos Download PDFInfo
- Publication number
- ES2612830T3 ES2612830T3 ES14180005.2T ES14180005T ES2612830T3 ES 2612830 T3 ES2612830 T3 ES 2612830T3 ES 14180005 T ES14180005 T ES 14180005T ES 2612830 T3 ES2612830 T3 ES 2612830T3
- Authority
- ES
- Spain
- Prior art keywords
- electric transport
- transport current
- current
- power supply
- controller
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000012377 drug delivery Methods 0.000 title claims abstract description 51
- 241001465754 Metazoa Species 0.000 claims abstract description 37
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 94
- 229940124597 therapeutic agent Drugs 0.000 claims description 25
- 238000012937 correction Methods 0.000 claims description 15
- 229940079593 drug Drugs 0.000 description 61
- 238000000034 method Methods 0.000 description 55
- 238000001647 drug administration Methods 0.000 description 51
- 230000004888 barrier function Effects 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- 239000003990 capacitor Substances 0.000 description 15
- 238000005259 measurement Methods 0.000 description 9
- 229920000768 polyamine Polymers 0.000 description 9
- 229940126585 therapeutic drug Drugs 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- -1 antibiotic Substances 0.000 description 7
- 229910052802 copper Inorganic materials 0.000 description 7
- 239000010949 copper Substances 0.000 description 7
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 229910021607 Silver chloride Inorganic materials 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- ZISSAWUMDACLOM-UHFFFAOYSA-N methyl-t-butylethan Natural products CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 6
- 229920006267 polyester film Polymers 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- 208000019695 Migraine disease Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229960003708 sumatriptan Drugs 0.000 description 4
- 229960000658 sumatriptan succinate Drugs 0.000 description 4
- 229920002799 BoPET Polymers 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 2
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 description 2
- 206010019476 Hemiplegic migraine Diseases 0.000 description 2
- 208000000060 Migraine with aura Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 229960002133 almotriptan Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229960005254 naratriptan Drugs 0.000 description 2
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920003223 poly(pyromellitimide-1,4-diphenyl ether) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 229960000425 rizatriptan Drugs 0.000 description 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229960001360 zolmitriptan Drugs 0.000 description 2
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010292 electrical insulation Methods 0.000 description 1
- 238000003487 electrochemical reaction Methods 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Electrotherapy Devices (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14137708P | 2008-12-30 | 2008-12-30 | |
| US141377P | 2008-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2612830T3 true ES2612830T3 (es) | 2017-05-18 |
Family
ID=41728042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14180005.2T Active ES2612830T3 (es) | 2008-12-30 | 2009-12-29 | Control electrónico de sistema de administración de fármacos |
| ES09803973.8T Active ES2526118T3 (es) | 2008-12-30 | 2009-12-29 | Control electrónico de sistema de administración de fármacos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09803973.8T Active ES2526118T3 (es) | 2008-12-30 | 2009-12-29 | Control electrónico de sistema de administración de fármacos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8983594B2 (enExample) |
| EP (3) | EP2393549B1 (enExample) |
| JP (2) | JP5888645B2 (enExample) |
| CN (2) | CN102333566B (enExample) |
| AU (2) | AU2009335085B2 (enExample) |
| BR (1) | BRPI0923808A2 (enExample) |
| CA (2) | CA2748569A1 (enExample) |
| EA (1) | EA201100891A1 (enExample) |
| ES (2) | ES2612830T3 (enExample) |
| HK (2) | HK1202083A1 (enExample) |
| IL (1) | IL213855A0 (enExample) |
| MX (1) | MX2011007137A (enExample) |
| NZ (2) | NZ622157A (enExample) |
| WO (1) | WO2010078313A1 (enExample) |
| ZA (1) | ZA201104832B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013012117A8 (pt) * | 2010-11-23 | 2017-10-10 | Nupathe Inc | Sistema de distribuição de fármaco iontoforético coempacotado de utilização única coempacotado autocontido, usos de fármaco e de composto de triptano |
| US8428708B1 (en) * | 2012-05-21 | 2013-04-23 | Incline Therapeutics, Inc. | Self-test for analgesic product |
| US8428709B1 (en) | 2012-06-11 | 2013-04-23 | Incline Therapeutics, Inc. | Current control for electrotransport drug delivery |
| US9744353B2 (en) | 2012-11-14 | 2017-08-29 | Teva Pharmaceuticals International Gmbh | Detection of presence and alignment of a therapeutic agent in an iontophoretic drug delivery device |
| FR3015300B1 (fr) * | 2013-12-20 | 2018-03-02 | L'oreal | Dispositif d'iontophorese a reservoir |
| DE112015003555T5 (de) * | 2014-08-01 | 2017-04-27 | Thorley Industries, Llc | Babytragende Stühle |
| PL3191170T3 (pl) * | 2014-09-08 | 2022-06-27 | Fastmeditalia S.R.L. | Plaster zdolny do wytwarzania mikroprądów |
| KR101912946B1 (ko) * | 2016-03-22 | 2018-10-29 | 이태규 | 생체정보 유효기간에 기초한 타임패치 장치 |
| CN106039568B (zh) * | 2016-06-23 | 2018-08-21 | 陈家林 | 一种穴位电子药灸治疗装置 |
| ES2885062T3 (es) | 2017-06-28 | 2021-12-13 | Fundacion Tecnalia Res & Innovation | Dispositivo para la administración transdérmica controlada y vigilada de principios activos y uso del mismo |
| US12109407B2 (en) | 2018-01-11 | 2024-10-08 | Theranica Bio-Electronics Ltd. | Electrode patch |
| KR102132370B1 (ko) * | 2018-03-13 | 2020-08-05 | 주식회사 지씨에스 | 피부관리장치, 피부관리장치의 구동방법 및 컴퓨터 판독가능 기록매체 |
| US11397455B2 (en) | 2018-09-10 | 2022-07-26 | Microsoft Technology Licensing, Llc | Managing DC power |
| WO2020082129A1 (en) * | 2018-10-23 | 2020-04-30 | Saluda Medical Pty Limited | "supervisor for implantable stimulation devices" |
| GB201818743D0 (en) * | 2018-11-16 | 2019-01-02 | Nicoventures Trading Ltd | System and method of consumption control |
| AU2020225481A1 (en) * | 2019-02-22 | 2021-10-14 | Pear Therapeutics (Us), Inc. | Systems and methods for the treatment of symptoms associated with migraines |
| CN110860029B (zh) * | 2019-10-09 | 2022-04-22 | 杭州未名信科科技有限公司 | 一种经皮给药贴及经皮给药方法 |
| JP7235862B2 (ja) * | 2020-04-27 | 2023-03-08 | ヤーマン株式会社 | 美容機器および電流制御方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4141359A (en) * | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
| US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
| US5961482A (en) * | 1986-07-25 | 1999-10-05 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
| US4927408A (en) | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
| US5047007A (en) * | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
| US5207752A (en) * | 1990-03-30 | 1993-05-04 | Alza Corporation | Iontophoretic drug delivery system with two-stage delivery profile |
| US5246418A (en) * | 1991-12-17 | 1993-09-21 | Becton Dickinson And Company | Iontophresis system having features for reducing skin irritation |
| US5499967A (en) * | 1992-02-27 | 1996-03-19 | Societe Anonyme Dite: Laboratoires D'hygiene Societe Anonyme Dite: Et De Dietetique (L.H.D.) | Transdermal drug delivery device with waveshape generator |
| FR2688106B1 (fr) | 1992-02-27 | 1994-09-09 | Lhd Lab Hygiene Dietetique | Dispositif de generation d'une tension electrique de forme d'onde predeterminee, appareil ionophoretique d'administration transdermique de medicaments. |
| IL105073A0 (en) * | 1992-03-17 | 1993-07-08 | Becton Dickinson Co | User activated iontophoretic device and method for using same |
| US5310404A (en) * | 1992-06-01 | 1994-05-10 | Alza Corporation | Iontophoretic delivery device and method of hydrating same |
| FI944321L (fi) * | 1992-11-05 | 1994-11-16 | Becton Dickinson Co | Käyttäjäaktivoitu iontoforeettinen laite ja menetelmä sen käyttämiseksi |
| US5254007A (en) * | 1993-01-29 | 1993-10-19 | Eagan Chris S | Baby entertainment and learning apparatus for highchairs |
| US5533971A (en) | 1993-09-03 | 1996-07-09 | Alza Corporation | Reduction of skin irritation during electrotransport |
| US5551953A (en) * | 1994-10-31 | 1996-09-03 | Alza Corporation | Electrotransport system with remote telemetry link |
| JPH08155041A (ja) * | 1994-12-05 | 1996-06-18 | Advance Co Ltd | イオントフォレシス用新規高能率電極システム |
| US5697896A (en) * | 1994-12-08 | 1997-12-16 | Alza Corporation | Electrotransport delivery device |
| US5879322A (en) | 1995-03-24 | 1999-03-09 | Alza Corporation | Self-contained transdermal drug delivery device |
| IE960312A1 (en) * | 1995-06-02 | 1996-12-11 | Alza Corp | An electrotransport delivery device with voltage boosting¹circuit |
| IE960375A1 (en) | 1995-06-05 | 1996-12-11 | Alza Corp | Device for transdermal electrotransport delivery of fentanyl¹and sufentanil |
| US6881208B1 (en) | 1995-06-05 | 2005-04-19 | Joseph B. Phipps | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
| US5983130A (en) * | 1995-06-07 | 1999-11-09 | Alza Corporation | Electrotransport agent delivery method and apparatus |
| US6167301A (en) * | 1995-08-29 | 2000-12-26 | Flower; Ronald J. | Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit |
| WO1997007853A1 (en) | 1995-08-31 | 1997-03-06 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis device and method of current control therefor |
| US5688232A (en) * | 1995-09-28 | 1997-11-18 | Becton Dickinson And Company | Iontophoretic drug delivery device having an improved controller |
| FR2747313B1 (fr) * | 1996-04-16 | 1998-06-05 | Lhd Lab Hygiene Dietetique | Dispositif d'administration transdermique de medicaments par ionophorese |
| US6086572A (en) * | 1996-05-31 | 2000-07-11 | Alza Corporation | Electrotransport device and method of setting output |
| ZA975326B (en) * | 1996-06-18 | 1998-01-14 | Alza Corp | Device and method for enhancing transdermal flux of agents being delivered or sampled. |
| US5738647A (en) * | 1996-09-27 | 1998-04-14 | Becton Dickinson And Company | User activated iontophoretic device and method for activating same |
| US5693024A (en) * | 1996-09-27 | 1997-12-02 | Becton Dickinson And Company | Iontophoretic drug delivery system, including method for determining hydration of patch |
| US6350259B1 (en) * | 1996-09-30 | 2002-02-26 | Vyteris, Inc. | Selected drug delivery profiles using competing ions |
| US20010009983A1 (en) * | 1997-09-29 | 2001-07-26 | Drug Delivery Technologies, Inc. | Methods for implementing current delivery profiles used in an iontophoretic system |
| EP1039950A1 (en) * | 1997-12-16 | 2000-10-04 | Alza Corporation | Regulator with artificial load to maintain regulated delivery |
| DE69837163T2 (de) * | 1997-12-17 | 2007-11-22 | Alza Corp., Mountain View | Iontophoretische vorrichtung mit programmierbarer elektrischer stromeinstellung |
| ATE424883T1 (de) * | 1999-04-12 | 2009-03-15 | Hisamitsu Pharmaceutical Co | Iontophoresevorrichtung |
| US6385488B1 (en) * | 1999-05-20 | 2002-05-07 | Vyteris, Inc. | Circuits for increasing the reliability of an iontophoretic system |
| US6377848B1 (en) * | 1999-08-25 | 2002-04-23 | Vyteris, Inc. | Devices activating an iontophoretic delivery device |
| EP1435945B1 (en) * | 2001-06-05 | 2008-08-13 | Aung-din, Ronald | Topical migraine therapy |
| US6708050B2 (en) * | 2002-03-28 | 2004-03-16 | 3M Innovative Properties Company | Wireless electrode having activatable power cell |
| FR2844719B1 (fr) * | 2002-09-24 | 2004-11-19 | Francois Duret | Dispositif electro-chimique pour le blanchiment d'un corps |
| US6745071B1 (en) | 2003-02-21 | 2004-06-01 | Birch Point Medical, Inc. | Iontophoretic drug delivery system |
| WO2006133101A2 (en) * | 2005-06-03 | 2006-12-14 | Trans-Dermal Patents Company, Llc | Agent delivery system |
| AU2007238685B2 (en) * | 2006-04-13 | 2012-09-13 | Teva Pharmaceuticals International Gmbh | Transdermal methods and systems for the delivery of anti-migraine compounds |
| EP2059297A4 (en) * | 2006-08-30 | 2009-12-30 | Lg Household & Health Care Ltd | IONTOPHORESIS DEVICE |
| US20080188791A1 (en) * | 2007-02-02 | 2008-08-07 | Difiore Attilio E | Active iontophoresis delivery system |
-
2009
- 2009-12-29 CN CN200980157664.6A patent/CN102333566B/zh not_active Expired - Fee Related
- 2009-12-29 NZ NZ622157A patent/NZ622157A/en not_active IP Right Cessation
- 2009-12-29 BR BRPI0923808-5A patent/BRPI0923808A2/pt not_active IP Right Cessation
- 2009-12-29 EP EP09803973.8A patent/EP2393549B1/en not_active Not-in-force
- 2009-12-29 JP JP2011544581A patent/JP5888645B2/ja not_active Expired - Fee Related
- 2009-12-29 MX MX2011007137A patent/MX2011007137A/es active IP Right Grant
- 2009-12-29 WO PCT/US2009/069673 patent/WO2010078313A1/en not_active Ceased
- 2009-12-29 ES ES14180005.2T patent/ES2612830T3/es active Active
- 2009-12-29 CA CA2748569A patent/CA2748569A1/en not_active Abandoned
- 2009-12-29 EP EP14180005.2A patent/EP2810688B1/en not_active Not-in-force
- 2009-12-29 EA EA201100891A patent/EA201100891A1/ru unknown
- 2009-12-29 US US12/648,726 patent/US8983594B2/en not_active Expired - Fee Related
- 2009-12-29 CA CA2944660A patent/CA2944660A1/en not_active Abandoned
- 2009-12-29 EP EP16175923.8A patent/EP3120895A1/en not_active Withdrawn
- 2009-12-29 NZ NZ593928A patent/NZ593928A/en not_active IP Right Cessation
- 2009-12-29 ES ES09803973.8T patent/ES2526118T3/es active Active
- 2009-12-29 AU AU2009335085A patent/AU2009335085B2/en not_active Ceased
- 2009-12-29 CN CN201410088686.4A patent/CN104043194A/zh active Pending
-
2011
- 2011-06-30 ZA ZA2011/04832A patent/ZA201104832B/en unknown
- 2011-06-30 IL IL213855A patent/IL213855A0/en not_active IP Right Cessation
-
2015
- 2015-02-05 US US14/615,249 patent/US20150151120A1/en not_active Abandoned
- 2015-03-13 HK HK15102566.3A patent/HK1202083A1/xx unknown
- 2015-06-10 HK HK15105508.7A patent/HK1205026A1/en unknown
- 2015-10-13 AU AU2015242986A patent/AU2015242986A1/en not_active Abandoned
-
2016
- 2016-02-04 JP JP2016019506A patent/JP2016104225A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL213855A0 (en) | 2011-07-31 |
| JP5888645B2 (ja) | 2016-03-22 |
| CN104043194A (zh) | 2014-09-17 |
| JP2012513876A (ja) | 2012-06-21 |
| AU2009335085A1 (en) | 2011-08-18 |
| HK1202083A1 (en) | 2015-09-18 |
| CA2944660A1 (en) | 2010-07-08 |
| EP2810688B1 (en) | 2016-11-16 |
| AU2015242986A1 (en) | 2015-11-05 |
| AU2009335085B2 (en) | 2015-11-05 |
| ZA201104832B (en) | 2016-03-30 |
| EP2393549A1 (en) | 2011-12-14 |
| EP3120895A1 (en) | 2017-01-25 |
| ES2526118T3 (es) | 2015-01-07 |
| EA201100891A1 (ru) | 2012-05-30 |
| NZ622157A (en) | 2015-10-30 |
| HK1162992A1 (en) | 2012-09-07 |
| EP2810688A2 (en) | 2014-12-10 |
| CN102333566B (zh) | 2014-03-26 |
| BRPI0923808A2 (pt) | 2015-07-14 |
| EP2810688A3 (en) | 2015-04-08 |
| US20100262066A1 (en) | 2010-10-14 |
| NZ593928A (en) | 2014-03-28 |
| US20150151120A1 (en) | 2015-06-04 |
| WO2010078313A1 (en) | 2010-07-08 |
| EP2393549B1 (en) | 2014-10-01 |
| CA2748569A1 (en) | 2010-07-08 |
| US8983594B2 (en) | 2015-03-17 |
| JP2016104225A (ja) | 2016-06-09 |
| MX2011007137A (es) | 2011-12-06 |
| CN102333566A (zh) | 2012-01-25 |
| HK1205026A1 (en) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2612830T3 (es) | Control electrónico de sistema de administración de fármacos | |
| ES2631681T3 (es) | Detección de la presencia y alineación de un agente terapéutico en un dispositivo iontoforético de administración de fármacos | |
| JP4361020B2 (ja) | イオントフォレシス薬物送達システム | |
| JP4442928B2 (ja) | 電子移動搬送デバイス及び該デバイスによる事象発生回数の表示方法 | |
| JP6363070B2 (ja) | 電気輸送薬物配送のための電流制御 | |
| Subramony et al. | Microprocessor controlled transdermal drug delivery | |
| AU2011332187B2 (en) | User-activated self-contained co-packaged iontophoretic drug delivery system | |
| US20090043244A1 (en) | Electrotransport Drug Delivery Device Adaptable to Skin Resistance Change | |
| HK1162992B (en) | Electronic control of drug delivery system | |
| Wouters et al. | Microelectrochemical systems for drug delivery |